Anaconda Biomed, a medtech startup, has received fresh financing for its endovascular technology. A Fierce Biotech report puts the amount at $53 million in the article's text, while the headline says $56 million.
The money is intended to help the company finish work on a pivotal trial for its endovascular project. The source does not specify the target condition, device mechanism, or trial endpoints.
The discrepancy in the reported figure is worth noting, but the core development is that Anaconda Biomed now has capital to advance a later-stage clinical program.